Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 2018, the company focuses on harnessing the power of monoclonal antibodies and other advanced technologies to create targeted treatments for various malignancies. With a commitment to addressing unmet medical needs, Pyxis Oncology has made significant strides in its research and development efforts, particularly in the realm of immuno-oncology. The company’s unique approach to drug development sets it apart in a competitive market, positioning it as a notable player in the oncology sector. As it continues to advance its pipeline of promising therapies, Pyxis Oncology remains dedicated to improving patient outcomes and redefining cancer treatment paradigms.
DitchCarbon Score
How does Pyxis Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pyxis Oncology, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pyxis Oncology, Inc.'s reported carbon emissions
Pyxis Oncology, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific climate commitments outlined. As such, there are no reported figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions. Additionally, the company has not established any formal reduction targets or initiatives related to climate action. In the absence of specific emissions data or commitments, it is unclear how Pyxis Oncology is addressing climate change within its operations or supply chain.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pyxis Oncology, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
